Some ASCO23 abstracts to grab your attention!

As we head into the annual meeting of the American Society of Clinical Oncology (ASCO), it’s time to review some key abstracts which may grab your attention.

Of course not all of these will be positive in nature, yet some are already planned for phase 3 investigation on the basis of some rather skimpy early data…

While at the other end of the extreme are some important data largely under many people’s radar.

Here we highlight a dozen examples of what’s coming this weekend, explain what to watch out for and offer some important caveats or questions to think about.

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by